Ultimovacs ASA

Oslo Stock Exchange ULTI.OL

Ultimovacs ASA Shareholders' Equity for the year ending December 31, 2024

Ultimovacs ASA Shareholders' Equity is NA for the year ending December 31, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Ultimovacs ASA Shareholders' Equity for the year ending December 31, 2023 was USD 27.43 M, a -40.13% change year over year.
Ultimovacs ASA Shareholders' Equity for the year ending December 31, 2022 was USD 45.81 M, a -31.81% change year over year.
Ultimovacs ASA Shareholders' Equity for the year ending December 31, 2021 was USD 67.18 M, a 18.03% change year over year.
Ultimovacs ASA Shareholders' Equity for the year ending December 31, 2020 was USD 56.92 M, a 12.41% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Oslo Stock Exchange: ULTI.OL

Ultimovacs ASA

CEO	Dr. Carlos de Sousa
IPO Date	June 3, 2019
Location	Norway
Headquarters	Ullernchausséen 64
Employees	17
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Key trends

Past 5 years